Sagimet Biosciences Inc.
SGMTDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
TVB-2640 25 mg (US)
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
TVB-2640
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TVB-2640 25 mg (US) | Phase 2 | MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis) | - | - |
TVB-2640 | Phase 2 | Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease | - | - |
MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
1 drug in this indication
Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sagimet Biosciences Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Sagimet Biosciences Inc.'s (SGMT) pipeline across Phase 2. Its lead program is TVB-2640 25 mg (US) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sagimet Biosciences Inc.'s next FDA catalyst?→
Sagimet Biosciences Inc.'s (SGMT) next tracked catalyst is a Earnings expected November 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGMT biotech catalysts?→
Add SGMT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sagimet Biosciences Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.